CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 282 enrolled
Drug / intervention
OPC-34712drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01456897
NCT01456897Phase 3Completed
CompareCT.gov

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Oct 21, 2011·Updated Dec 30, 2019

In Brief

A Phase 3 clinical trial evaluating OPC-34712 for Schizophrenia. Completed, enrolled 282 participants across 1 site.

Detailed Summary

To investigate the safety and efficacy of long-term administration of OPC-34712 in patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 21, 2011
Enrollment StartOct 1, 2011
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.7 years ago

Interventions

OPC-34712drug

orally administered once daily